The European Study on Glycogen Storage Disease Type I guidelines originate from 2002 and recommend screening for malignant transformation from HCA to HCC by imaging (ultrasound and MRI‐scan) and by serum alpha‐fetoprotein (AFP) and carcino‐embryonic antigen (CEA).3 This evidence concerns the gene CEACAM5 and hepatocellular adenoma.